

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

NCT06354179

Status	RECRUITING
Phase	Phase 4
Sponsor	University Hospital, Limoges
Enrollment	162 participants

Key Eligibility Criteria

Inclusion (5)

- Recipients of a first liver allograft from a deceased donor
- Transplanted for less than four weeks at enrolment.
- Without inter-current progressive life-threatening or graft-threatening disease.
- Having signed a written informed consent for their participation in the study.
- Affiliated to, or beneficiary of, a social security regimen

Exclusion (12)

- Recipients of a split-liver transplantation.
- Recipients of any transplanted organ other than the liver
- Patient who has undergone colon resection
- Patients under legal protection (guardianship, curatorship).
- Patient presenting any contra-indication to tacrolimus or to MMF according to the summary of product characteristics (SmPC) of ENVARUSUS®, ADVAGRAF® and CELLCEPT®.

... and 7 more (see full listing online)

Locations (18 total)

CHU de Besançon - Hôpital Jean Minjot, Besançon, France
Beaujon hospital - APHP, Clichy, France
CHU de Dijon Bourgogne, Dijon, France
... and 15 more locations